The science, economics, and effectiveness of combination therapy for hepatitis C.
Dusheiko
G
G
Royal Free and University College School of Medicine, Hampstead, London, UK.
Barnes
E
E
Webster
G
G
Whalley
S
S
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D012254:Ribavirin